This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
by Zacks Equity Research
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
by Zacks Equity Research
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.
bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn
by Zacks Equity Research
bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study
by Zacks Equity Research
Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.
Theravance's (TBPH) Hypotension Study Misses Primary Goal
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now
by Zacks Equity Research
AVROBIO, Inc. (AVRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks
by Zacks Equity Research
AVROBIO, Inc. (AVRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?
by Zacks Equity Research
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.
AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVROBIO, Inc. (AVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.
5 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.
AVROBIO Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
AVROBIO has been struggling lately, but the selling pressure may be coming to an end soon
Why Earnings Season Could Be Great for AVROBIO (AVRO)
by Zacks Equity Research
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is AVROBIO (AVRO) Stock a Solid Choice Right Now?
by Zacks Equity Research
AVROBIO (AVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AVROBIO, Inc. (AVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVROBIO, Inc. (AVRO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AVROBIO, Inc. (AVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).